Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pegaspargase

View Patient Information
A complex of polyethylene glycol conjugated with L-asparaginase. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle. The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase.
Synonym:L-asparaginase with polyethylene glycol
PEG-asparaginase
PEG-L-asparaginase
PEG-L-asparaginase(K-H)
polyethylene glycol-L-asparaginase
US brand name:Oncaspar
Abbreviation:PEG-ASP
PEGLA
Chemical structure:(monomethoxypolyethylene glycol succinimidyl)74-L-asparaginase
IND number:3777
4056
NSC code:624239
644954
Search NCI's Drug Dictionary